Trial Profile

A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 17 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Rucaparib (Primary)
Indications Adenocarcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Sarcoma; Squamous cell cancer
Focus Therapeutic Use
Acronyms Clovis-001

Most Recent Events

07 Aug 2023 Planned End Date changed from 1 Jun 2023 to 1 Sep 2023.
08 May 2023 Planned End Date changed from 1 Apr 2023 to 1 Jun 2023.
13 Mar 2023 Planned End Date changed from 1 Feb 2023 to 1 Apr 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com